<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wei L</submitter><funding>National Natural Science Foundation of China</funding><pagination>e043436</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8039220</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(4)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>To summarise current evidence on the use of pentoxifylline (PTX) to prevent contrast-induced nephropathy (CIN).&lt;h4>Methods&lt;/h4>The PubMed, Embase and CENTRAL databases were searched for randomised controlled trials including patients with and without PTX undergoing contrast media exposure. We analysed the incidence of CIN and serum creatinine changes before and after contrast media exposure. All statistical analyses were conducted with Review Manager V.5.3.&lt;h4>Results&lt;/h4>We finally enrolled in seven randomised controlled trials with a total of 1484 patients in this analysis. All of seven included studies were performed in patients undergoing angioplasty or stenting. The overall rates of CIN were 8.8% and 10.4% in the PTX groups and control groups, respectively. However,</pubmed_abstract><journal>BMJ open</journal><pubmed_title>Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials.</pubmed_title><pmcid>PMC8039220</pmcid><funding_grant_id>2017YFC1308102</funding_grant_id><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Li D</pubmed_authors><pubmed_authors>Wei L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials.</name><description>&lt;h4>Objectives&lt;/h4>To summarise current evidence on the use of pentoxifylline (PTX) to prevent contrast-induced nephropathy (CIN).&lt;h4>Methods&lt;/h4>The PubMed, Embase and CENTRAL databases were searched for randomised controlled trials including patients with and without PTX undergoing contrast media exposure. We analysed the incidence of CIN and serum creatinine changes before and after contrast media exposure. All statistical analyses were conducted with Review Manager V.5.3.&lt;h4>Results&lt;/h4>We finally enrolled in seven randomised controlled trials with a total of 1484 patients in this analysis. All of seven included studies were performed in patients undergoing angioplasty or stenting. The overall rates of CIN were 8.8% and 10.4% in the PTX groups and control groups, respectively. However,</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2025-04-18T21:38:35.818Z</modification><creation>2025-04-07T09:24:23.855Z</creation></dates><accession>S-EPMC8039220</accession><cross_references><pubmed>33945499</pubmed><doi>10.1136/bmjopen-2020-043436</doi></cross_references></HashMap>